Clinical trials have studied continuous use up to 24 weeks with sustained benefits
1 Total Trials 1 Recruiting 0 Active 0 Completed Sponsor: Hudson Biotech Completed: 2028-03-17 Research Library 385 Papers Research data sourced from OpenAlex
Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Most people report feeling the effects within 48 to 72 hours of the first dose
President Biden signed the FDA Modernization Act 2.0 into law, with strong bipartisan support, to speed up the discovery process, lower the costs of new life-saving treatments, and reduce animal testing (217)
Common Bacteriostatic Water Mistakes 1